The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×

To the Editor: Modafinil is the first-line treatment for narcolepsy. It may also improve mood in narcoleptic patients (1). However, psychostimulants may exacerbate psychotic symptoms in psychotic patients (2). Cases of psychosis have also been reported during psychostimulant abuse (3) and during abuse of prescribed drug in narcoleptic patients (4) but not following medical use. Here we report the case of a boy with narcolepsy.

Albert was a 17-year-old boy who was diagnosed with narcolepsy at age 14. He was first prescribed modafinil, 400 mg/day for 1 year, switched to methylphenidate, 40 mg/day for 2 years, then returned to modafinil, 400 mg/day. The switching was because of complaints of irritability and of a lack of efficacy for sleep attacks. Albert then experienced flight of ideas, sexual excitation, and increased irritability. These manic symptoms resulted in friction with family members and a fight for which he could have been put on trial. Then, free of psychostimulant treatment, Albert was described as sad, anhedonic, and withdrawn. Following reintroduction of modafinil, the same manic symptoms reoccurred. After a meeting with a judge, Albert experienced self-referential thinking and suspiciousness. Later, a full manic episode developed within 3 days, including insomnia, tachypsychia, logorrhea, psychomotor agitation, and mood-incongruent psychosis. There was no grandiosity but delusion of persecution, based on auditory hallucinations (his uncle reproaching him for his past sexual behavior), complex visual hallucinations (a vampire hiding in his bedroom and trying to bite him), and a feeling of being talked to through the television. Albert was hospitalized, and the modafinil was stopped. The mania required pharmacological treatment that started after written consent was obtained from both Albert and his parents.

These mood symptoms seem time-related to psychostimulant administration and interruption. Exposure lasted for only 3 years, but discontinuation and reintroduction might have lowered the manic threshold. Contrary to previous reports of psychosis induced by psychostimulant abuse (3), the patient showed no trend toward dose escalation. This could be the first report of mania under a therapeutic dose of modafinil. The symptoms were compatible with psychostimulant-induced psychosis. Although an independent psychiatric disorder cannot be ruled out, we suggest a careful psychiatric monitoring of patients receiving modafinil and other psychostimulants for the treatment of narcolepsy.

References

1. Becker PM, Schwartz JR, Feldman NT, Hughes RJ: Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy. Psychopharmacology (Berl) 2004; 171:133–139Crossref, MedlineGoogle Scholar

2. Narendran R, Young CM, Valenti AM, Nickolova MK, Pristach CA: Is psychosis exacerbated by modafinil? (letter). Arch Gen Psychiatry 2002; 59:292–293Crossref, MedlineGoogle Scholar

3. Spensley J, Rockwell DA: Psychosis during methylphenidate abuse. N Engl J Med 1972; 286:880–881Crossref, MedlineGoogle Scholar

4. Leong GB, Shaner AL, Silva JA: Narcolepsy, paranoid psychosis, and analeptic abuse. Psychiatr J Univ Ott 1989; 14:481–483MedlineGoogle Scholar